Cabergoline Uses, Side Effects & Warnings

Doses of cabergoline up to 4.5 mg per week have been used in hyperprolactinaemic patients. Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient’s response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered. Patients receiving long term treatment with Cabergoline should undergo periodic assessment of their cardiac status and echocardiography should be considered.

• If you have an allergic reaction, call your doctor or local poison control center right away.
• It can cause dizziness, especially during the first few days of treatment.
• The incidence of the most common adverse events during the placebo-controlled study is presented in the following table.
• If conception occurs during therapy, treatment should be discontinued as soon as pregnancy is confirmed to limit foetal exposure to the drug.

Cabergoline prevents/suppresses physiological lactation by inhibiting prolactin secretion. After parturition, when the mother elects not to breast feed the infant or when breast feeding is contraindicated due to medical reasons related to the mother or the new-born. Patient aims to help the world proactively manage its healthcare, supplying evidence-based information on a wide range of medical and health topics to patients and health professionals. If you are due to have an operation or dental treatment, tell the person carrying out the treatment which medicines you are taking. It can cause dizziness, especially during the first few days of treatment.

Indications and Usage for Cabergoline

Preclinical safety studies of anabolic steroids indicate a consistent safety margin for this compound in rodents and in monkeys, as well as a lack of teratogenic, genotoxic or carcinogenic potential. • Renal insufficiency or ureteral/abdominal vascular obstruction that may occur with pain in the loin/flank, and lower limb oedema, as well as any possible abdominal masses or tenderness that may indicate retroperitoneal fibrosis. • Pleuro-pulmonary disease, such as dyspnoea, shortness of breath, persistent cough, or chest pain. • Evidence of cardiac valvulopathy as determined by pre-treatment echocardiography (see section 4.4).

Interactions

• History of pulmonary, pericardial and retroperitoneal fibrotic disorders. The benefit of continued treatment should be regularly reassessed taking into account the risk of fibrotic reactions and valvulopathy (see sections 4.3, 4.4 and 4.8). • Renal insufficiency or ureteral/abdominal vascular obstruction that may occur with pain in the loin/flank and lower limb oedema as well as any possible abdominal masses or tenderness that may indicate retroperitoneal fibrosis.

Other uses for this medicine

In both animals and humans, Cabergoline is extensively metabolized, predominately via hydrolysis of the acylurea bond or the urea moiety. Cabergoline does not cause enzyme induction and/or inhibition in the rat. Hydrolysis of the acylurea or urea moiety abolishes the prolactin-lowering effect of Cabergoline, and major metabolites identified thus far do not contribute to the therapeutic effect. If pregnancy is confirmed during therapy, then cabergoline should be discontinued to minimise foetal exposure. However, Briggs (2011) states that there is no evidence that exposure to cabergoline during pregnancy is harmful.